A total of 250 participants read a case summary and partial transcript including the expert testimony of a neuropsychologist who evaluated the plaintiff for a suspected mild traumatic brain injury (mTBI) in a personal injury trial. There were three diagnostic conditions (organic injury, psychogenic reaction, or malingering) to which participants were randomly assigned, along with two requested award amounts ($10,000 or $5 million). Both pre- and postdeliberation effects emerged for the diagnosis (largest awards for the organic mTBI condition) and for the award request (larger requests resulted in larger awards), with the effect size for award request being substantially larger than the clinical diagnosis. A significant interaction also emerged, whereby the effect of the clinical diagnosis was only present when the award request was large. Thus, factors that are potentially less relevant to pain and suffering (award request) may disproportionately impact mock juror decisions in personal injury trials relative to factors that should be more salient (the expert witness's diagnosis). However, the award request had no impact on mock juror perceptions of the injury's life impact, sympathy for the plaintiff, or perceived plaintiff credibility, but the diagnosis did influence these outcomes. Implications for civil litigation in mTBI trials are discussed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818234PMC
http://dx.doi.org/10.1080/13218719.2018.1442628DOI Listing

Publication Analysis

Top Keywords

award request
24
clinical diagnosis
12
mock juror
12
personal injury
8
request larger
8
diagnosis award
8
impact mock
8
award
7
diagnosis
6
request
6

Similar Publications

Doctoral education for physician assistants/associates: trends and characteristics in the U.S.

BMC Med Educ

January 2025

Physician Assistant Leadership and Learning Academy, University of Maryland, 520 West Fayette St, Suite 130, 21201, Baltimore, Maryland, USA.

Background: PA-specific post professional doctoral programs have gained traction in the U.S. over the past decade, but little is known about their structure and outcomes.

View Article and Find Full Text PDF

Introduction: Medication regimen complexity may be an important risk factor for adverse outcomes in older adults with heart failure. However, increasing complexity is often necessary when prescribing guideline-directed medical therapy at the time of a heart failure hospitalization. We sought to determine whether increased medication regimen complexity following a heart failure hospitalization was associated with worse post-hospitalization outcomes.

View Article and Find Full Text PDF

Aims/hypothesis: Insulin resistance and compensatory hyperinsulinaemia are core features leading to beta cell failure in youth-onset type 2 diabetes. Insulin clearance (IC) is also a key regulator of insulin concentrations, but few data exist on IC in youth-onset type 2 diabetes. In a secondary analysis of our Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) randomised clinical trial, we investigated potential sex-, race-, ethnicity- and treatment-related differences in IC in youth-onset type 2 diabetes and aimed to identify metabolic phenotypes associated with IC at baseline and in response to metformin, metformin plus a lifestyle intervention, and metformin plus rosiglitazone.

View Article and Find Full Text PDF

Half-Life Extension of the IgG-Degrading Enzyme (IdeS) Using Fc-Fusion Technology.

Eur J Immunol

December 2024

Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, CNRS, Sorbonne Université, Université Paris Cité, Paris, France.

Imlifidase (IdeS) is a bacterial protease that hydrolyzes human IgG in their hinge region, decreasing their half-life and abrogating their Fc-mediated properties. It is now successfully used in therapy to prevent graft rejection during kidney transplants and is being clinically evaluated in several IgG-mediated autoimmune diseases. IdeS short half-life however limits its clinical use, particularly in the case of chronic diseases that would request repeated administrations.

View Article and Find Full Text PDF

Background And Objective: We conducted an opportunistic pharmacokinetic study to evaluate the population pharmacokinetics of meropenem, an antimicrobial commonly used to treat Gram-negative infections in adults of different ages, including older adults, and determined optimal dosing regimens.

Methods: A total of 99 patients were included. The population pharmacokinetic models used had two compartments: zero-order input and linear elimination.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!